CTI was founded in 1999 by a small group of innovative thinkers who wanted to change the lives of chronically and critically ill patients.

More About Our Leadership
infinity symbol

From a small team in an old carriage house to associates in more than 60 countries across the world.

We have now worked on more than 6000 projects, worked on every continent except Antarctica, and have contributed to more than 100 new drug and device approvals through global regulatory agencies such as the FDA, EMA, and others. Currently, we work with more than 200 pharmaceutical and emerging biotechnology and medical device companies.

More about our history
Four CTI employees enjoying each other's company.
infinity symbol

Join the CTI team

Learn more about the unique CTI culture and browse through our open positions.

Learn More

Drug/Device Approvals

CTI has contributed to more than 100 new drug and device approvals through global regulatory agencies such as the FDA, EMA, and others. Our approvals have been in therapeutic areas including:

  • Acne
  • Acute Graft vs Host Disease
  • Asthma
  • β-thalassemia
  • Binge Eating Disorder
  • Chronic Liver Disease
  • Device
  • Endometriosis
  • Glycemic Control
  • Hereditary Transthyretin-mediated Amyloidosis
  • Hypoactive Sexual Desire
  • Insomnia
  • Kidney Transplantation
  • LAL Deficiency/
  • MPS III
  • Lymphangioleiomyomatosis – 1st approved treatment
  • Macular Degeneration
  • Major Depressive Disorder
  • Migraine
  • Narcolepsy
  • Obstructive Sleep Apnea
  • Oncology – 1st biosimilar approved in US
  • Oncology/ Drug Toxicity- 1st/only antidote for emergency treatment
  • Osteoarthritis pain
  • Paroxysmal Nocturnal Hemoglobinuira
  • Pediatric Short Bowel Syndrome
  • Phenylketonuria
  • Rheumatoid Arthritis
  • Sickle Cell
  • Submental fullness
  • Surgical Seal
  • Thrombocytopenia
  • Type II Diabetes
  • Ulcerative Colitis
  • Weight Management